biuro@scopefluidics.com
+48 22 376 21 14
About
Team
Our offer
Knowledge base
News
Investor relations
Career
Contact
biuro@scopefluidics.com
+48 22 376 21 14
About
Team
Our offer
Knowledge base
News
Investor relations
Career
Contact
biuro@scopefluidics.com
+48 22 376 21 14
RAPORT EBI 12/2017 | 18-10-2017 | Objęcie warrantów subskrypcyjnych oraz akcji serii D
Previous Post
RAPORT ESPI 6/2017 | 18-10-2017 | Otrzymanie zawiadomienia od osoby pełniącej obowiązki zarządcze
Next Post
RAPORT ESPI 7/2017 | 06-11-2017 | Zakończenie etapu prac nad projektem PCR|ONE
0
Shares
Related Posts
29.10.2026
Scope Fluidics begins efforts toward certification of the rapid BACTEROMIC panel for Gram-negative bacteria, which could go on sale in 2027
SCOPE FLUIDICS
0
15.10.2026
Edocera develops device prototype and confirms its ability to detect signs of stroke
SCOPE FLUIDICS
0
30.09.2026
Scope Fluidics after the first half of 2026: strong cash position, IVDR certification and expanding cooperation with distributors
SCOPE FLUIDICS
0